PURPOSE: Our goal was to evaluate the contribution of double phase CT arteriography (CTA) of the whole liver to differentiate hepatic tumors from false-positive areas on CT during arterial portography (CTAP). METHODS: In 38 candidates for surgical resection of hepatic tumors, both CTAP and double phase CTA were performed. A total of 68 perfusion defects were identified at CTAP. Of 68 perfusion defects, 47 were found to represent hepatic tumors [hepatocellular carcinoma (HCC), n = 31; hepatic metastasis, n = 13; cholangiocarcinoma n = 2; focal nodular hyperplasia, n = 1]. The other 21 perfusion defects were defined as perfusion abnormalities in which focal hepatic masses had not been identified at surgery or pathologic analysis. The phase one CTA scanning started 12 s after the beginning of the injection of contrast material, and the phase two CTA scanning started 20 s after the end of the phase one CTA, with 60 ml of contrast agent (150 mg I/ml) injected at a rate of 2 ml/s. RESULTS: On phase one CTA, only 1 lesion in 31 HCCs showed rim enhancement and 26 HCCs (84%) had rim enhancement on phase two CTA. Twelve lesions (80%) of the hepatic metastases and cholangiocarcinomas had rim enhancement on phase one CTA and 11 lesions (73%) showed rim enhancement on phase two CTA. Twenty-one perfusion abnormalities on CTAP did not show rim enhancement on either phase one or phase two CTA. CONCLUSION: Double phase CT arteriography of the whole liver was useful to differentiate hepatic tumors from perfusion abnormalities on CTAP.
PURPOSE: Our goal was to evaluate the contribution of double phase CT arteriography (CTA) of the whole liver to differentiate hepatic tumors from false-positive areas on CT during arterial portography (CTAP). METHODS: In 38 candidates for surgical resection of hepatic tumors, both CTAP and double phase CTA were performed. A total of 68 perfusion defects were identified at CTAP. Of 68 perfusion defects, 47 were found to represent hepatic tumors [hepatocellular carcinoma (HCC), n = 31; hepatic metastasis, n = 13; cholangiocarcinoma n = 2; focal nodular hyperplasia, n = 1]. The other 21 perfusion defects were defined as perfusion abnormalities in which focal hepatic masses had not been identified at surgery or pathologic analysis. The phase one CTA scanning started 12 s after the beginning of the injection of contrast material, and the phase two CTA scanning started 20 s after the end of the phase one CTA, with 60 ml of contrast agent (150 mg I/ml) injected at a rate of 2 ml/s. RESULTS: On phase one CTA, only 1 lesion in 31 HCCs showed rim enhancement and 26 HCCs (84%) had rim enhancement on phase two CTA. Twelve lesions (80%) of the hepatic metastases and cholangiocarcinomas had rim enhancement on phase one CTA and 11 lesions (73%) showed rim enhancement on phase two CTA. Twenty-one perfusion abnormalities on CTAP did not show rim enhancement on either phase one or phase two CTA. CONCLUSION: Double phase CT arteriography of the whole liver was useful to differentiate hepatic tumors from perfusion abnormalities on CTAP.